Skip to main content

Advertisement

ADVERTISEMENT

Exclusives

News
03/05/2024
VCEL noted CMS granted NexoBrid a permanent J code and transitional pass-through payment status as of Jan 1st and provides a reimbursement pathway for the outpatient treatment of NexoBrid patients in its target burn centers. VCEL Q423...
VCEL noted CMS granted NexoBrid a permanent J code and transitional pass-through payment status as of Jan 1st and provides a reimbursement pathway for the outpatient treatment of NexoBrid patients in its target burn centers. VCEL Q423...
VCEL noted CMS granted NexoBrid...
03/05/2024
Wound Care
News
03/05/2024
MiMedx noted it continues to work internally and externally on options to expand its skin substitute portfolio beyond amniotic tissue to include xenografts and/or synthetics to improve its addressable market. MDXG Q423 Earnings Transcript on...
MiMedx noted it continues to work internally and externally on options to expand its skin substitute portfolio beyond amniotic tissue to include xenografts and/or synthetics to improve its addressable market. MDXG Q423 Earnings Transcript on...
MiMedx noted it continues to...
03/05/2024
Wound Care
News
03/05/2024
SNN shared they have made investments in AWC where there is a gap between themselves and competitive offerings. In about 18 months there will be new product offerings to make SNN more competitive from a product lineup standpoint. SNN Q423...
SNN shared they have made investments in AWC where there is a gap between themselves and competitive offerings. In about 18 months there will be new product offerings to make SNN more competitive from a product lineup standpoint. SNN Q423...
SNN shared they have made...
03/05/2024
Wound Care
News
03/05/2024
A study assessed the economic implications of AbClo vs NPWT on open abdomen management. The study found that AbClo was associated with lower incremental costs of -$6,012 (95% CI -$19 449 to +$1996). The probability that AbClo was cost-savings...
A study assessed the economic implications of AbClo vs NPWT on open abdomen management. The study found that AbClo was associated with lower incremental costs of -$6,012 (95% CI -$19 449 to +$1996). The probability that AbClo was cost-savings...
A study assessed the economic...
03/05/2024
Wound Care
News
03/05/2024
Researchers from USC, in partnership with Healogics, have produced a model to predict healing and identify wounds most likely to heal within 12 weeks. The model utilizes EMR data from over 600,000 wounds, enabling highly predictive...
Researchers from USC, in partnership with Healogics, have produced a model to predict healing and identify wounds most likely to heal within 12 weeks. The model utilizes EMR data from over 600,000 wounds, enabling highly predictive...
Researchers from USC, in...
03/05/2024
Wound Care
News
03/05/2024
A 45-patient study will evaluate the effectiveness of different dosages of energy of extracorporeal shock wave therapy (ECSW) in the treatment of post-mastectomy lymphedema volume and quality of life (QoL). The estimated study completion date...
A 45-patient study will evaluate the effectiveness of different dosages of energy of extracorporeal shock wave therapy (ECSW) in the treatment of post-mastectomy lymphedema volume and quality of life (QoL). The estimated study completion date...
A 45-patient study will evaluate...
03/05/2024
Wound Care
News
03/05/2024
Avita shared the opportunity with hospitals for full-thickness skin defects with RECELL is significantly larger than burns; there are 35,000 RECELL-eligible burn patients and ~400,000 RECELL-eligible full-thickness skin defect patients. RCEL...
Avita shared the opportunity with hospitals for full-thickness skin defects with RECELL is significantly larger than burns; there are 35,000 RECELL-eligible burn patients and ~400,000 RECELL-eligible full-thickness skin defect patients. RCEL...
Avita shared the opportunity...
03/05/2024
Wound Care
News
03/05/2024
Cynata Therapeutics announced the initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in DFUs. Median percent reduction in wound surface area in the active CYP-006TK group after 10 weeks...
Cynata Therapeutics announced the initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in DFUs. Median percent reduction in wound surface area in the active CYP-006TK group after 10 weeks...
Cynata Therapeutics announced...
03/05/2024
Wound Care
Preview Image
Partner Content
03/05/2024
SmartTRAK forecasts the WW Advanced Wound Dressing Market will grow at a 5-year CAGR of +5.2%. The market grew +5.2% in Q323 and +5.6% in the first three quarters of 2023.
SmartTRAK forecasts the WW Advanced Wound Dressing Market will grow at a 5-year CAGR of +5.2%. The market grew +5.2% in Q323 and +5.6% in the first three quarters of 2023.
SmartTRAK forecasts the WW...
03/05/2024
Wound Care
News
02/26/2024
Avita plans to integrate PermeaDerm Biosynthetic Wound Matrix into its selling portfolio with plans to launch PermeaDerm in March 2024. In Jan, Avita announced an exclusive multi-year distribution agreement with Stedical Scientific to...
Avita plans to integrate PermeaDerm Biosynthetic Wound Matrix into its selling portfolio with plans to launch PermeaDerm in March 2024. In Jan, Avita announced an exclusive multi-year distribution agreement with Stedical Scientific to...
Avita plans to integrate...
02/26/2024
Wound Care

Advertisement

Advertisement

Advertisement